Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VertiFlex's Superion

This article was originally published in The Gray Sheet

Executive Summary

VertiFlex plans to file a pre-market approval application in 2013 for its Superion interspinous spacer to percutaneously treat spinal stenosis. The firm has enrolled 173 patients to date in a randomized, pivotal non-inferiority trial comparing Superion with St. Francis Medical Technologies' X-Stop. The latter device was the first interspinous spacer, approved by FDA in November 2005 (1"The Gray Sheet" Nov. 23, 2005). VertiFlex says it plans to complete trial enrollment during the first half of 2011 and will follow patients for two years. On Aug. 27, VertiFlex announced the divestiture of its Silverbolt percutaneous pedicle screw system for $3.5 million to Exactech. Silverbolt generates $6 million in sales annually and will complement Exactech's current spine product portfolio. The move will allow VertiFlex to refocus on Superion, which the firm expects to be its future primary revenue driver. While Silverbolt competes with numerous similar products, Superion would be unique as the only percutaneous interspinous spacer on the market following its approval, the firm explains. Superion gained a CE mark in 2007 and is already available overseas. Privately-held VertiFlex, located in San Clemente, Calif., was founded in 2005 and has raised $64 million in capital to date
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT029355

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel